Small Intestine-Permeable Cyclic Peptide-Based Technology Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized Insulin Hexamer and Its Analogs in Diabetic Mice
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c00902 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Shoma Chikamatsu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-09…. Hauptthemen laut MEDLINE: Insulin, Diabetes Mellitus, Experimental, Intestine, Small, Hypoglycemic Agents. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Kumamoto University, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Oral administration of protein therapeutics, such as insulin, is hindered by enzymatic degradation and poor intestinal permeability. To overcome these barriers, we present a peptide-based delivery platform that uses a DNP peptide that is permeable in the small intestine. We engineered DNP-V, a modular carrier peptide, fused to an insulin-interacting peptide. We demonstrated that the coadministration of DNP-V with zinc-stabilized insulin hexamers in diabetic mice enables a rapid, robust, and sustained reduction in blood glucose levels to near-normal levels. This effect was reproducible across multiple diabetic models, achieving significant suppression of the initial postprandial glucose surge with once-daily oral dosing. This platform can be easily applied to long-acting insulin analogs, allowing for oral delivery without the need for complex preparation changes. Additionally, covalent conjugation of DNP peptides to insulin via click chemistry yielded stable insulin conjugates that significantly enhanced intestinal absorption and produced comparable oral glucose-lowering effects. This confirms the direct contribution of the carriers to the absorption. These findings establish DNP peptides as versatile, modular platforms for the oral delivery of macromolecular therapeutics. As long as an appropriate conjugatable partner is available, this technology can simply and effectively convert injectable biopharmaceuticals into orally administrable forms, offering a promising path to practical, patient-friendly oral therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
- Department of Pharmaceutical Microbiology, School of Pharmacy, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
- Department of Biological Chemistry, Graduate School of Science, Osaka Metropolitan University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.
- Laboratory of Developmental Genetics, Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.
- Center for Metabolic Regulation of Healthy Aging, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
- School of Life Science and Technology, Tokyo Institute of Technology, 4259-B-25 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan.
ORCID-Profile: Sumio Ohtsuki, Shingo Ito
Förderung
- Kumamoto University
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Support for Pioneering Research Initiated by the Next Generation
- Center for Clinical and Translational Research in Kyushu University Seeds A
Zitieren
APA
Chikamatsu, S., Sakaguchi, K., Michigami, M., Araki, K., Kume, S., Tokuyasu, M., Masuda, T., Fujii, I., Ohtsuki, S., & Ito, S. (2026). Small Intestine-Permeable Cyclic Peptide-Based Technology Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized Insulin Hexamer and Its Analogs in Diabetic Mice. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00902
Vancouver
Chikamatsu S, Sakaguchi K, Michigami M, Araki K, Kume S, Tokuyasu M, et al. Small Intestine-Permeable Cyclic Peptide-Based Technology Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized Insulin Hexamer and Its Analogs in Diabetic Mice. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c00902
BibTeX
@article{Chikamatsu2026,
author = {Chikamatsu, Shoma and Sakaguchi, Kosei and Michigami, Masataka and Araki, Kimi and Kume, Shoen and Tokuyasu, Midori and Masuda, Takeshi and Fujii, Ikuo and Ohtsuki, Sumio and Ito, Shingo},
title = {Small Intestine-Permeable Cyclic Peptide-Based Technology Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized Insulin Hexamer and Its Analogs in Diabetic Mice},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c00902}
}
EUVIMED